FILTER
FILTERED INTERVIEW RESULTS
Shuang Liu
CEO & FOUNDER, CONSYNANCE THERAPEUTICS
"Although each rare disease impacts a small population, the rare disease population is estimated to be 10% of the total population, meaning 25-30 million Americans have at least one rare condition."
Jay Roberts & Robert Fremeau
PRESIDENT AND CEO & CHIEF SCIENTIFIC OFFICER, VYANT BIO
"At Vyant Bio we are reinventing how drugs are discovered for complex neurological and neurodegenerative disorders by applying a human-first approach."
Andrea Pfeifer
CO-FOUNDER & CEO, AC IMMUNE
"AC Immune is combining diagnostics and therapeutics, and it has developed the tools to enable detection and clearance of specific pathological proteins underlying neurodegenerative diseases."
Trevor P. Castor
PRESIDENT & CEO, APHIOS CORPORATION
"In 2021, we focused on introducing our green pathogen reduction technology to biotechnology and pharmaceutical companies."
Jeff Butler
PRESIDENT, AMPAC FINE CHEMICALS, AN SK PHARMTECO COMPANY
"Outside of our manufacturing capabilities, AFC is investing and featuring AMPAC Analytical given the growing demand for pharmaceutical testing services."
Louis Kassa
PRESIDENT & CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"Our blueprint to success has manifested in six IPOs and over US$3 billion worth of company value created."
Jan Kengelbach
CEO, AENOVA GROUP
"While it's always easier to deny a certain service if you don't yet have the technical expertise in a particular area, in the long-term it is advantageous to explore the possibility of investing in that area with the customer."
Russell Trenary
PRESIDENT & CEO, OUTLOOK THERAPEUTICS
"If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."
Albert Friesen
CEO & CHAIRMAN OF THE BOARD, MEDICURE INC.
"Our recently launched e-commerce site for Marley Drug has huge potential and will be our most significant driver of growth and major source of our profits moving forward."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Mexico Chemicals 2024
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
